Based on these findings, serum syndecan‐1 has been proposed as an independent prognostic biomarker of MM [239, 243], and indeed the evidence for syndecan‐1 is stronger than decorin [245, 246] or versican [247]. This evidence concerns the gene DCN and Miyoshi myopathy.